• Portfolio
  • Latest Articles

CLINICAL TRIALS

October 21st

Imugene to demonstrate the benefits of combination tumor treatment

  Archived
Rat's Rant: What's hot, what's not and ... The Canberra Raiders

October 1st 2019

Rat's Rant: What's hot, what's not and ... The Canberra Raiders

A healthy six pack in a hot sector: Part 2

September 11th 2019

A healthy six pack in a hot sector: Part 2

Imagion MRI applications as a new source of revenue

September 9th 2019

Imagion MRI applications as a new source of revenue

Immuron shares soar more than 20%

September 4th 2019

Immuron shares soar more than 20%

Immuron delivers another year of strong sales growth

September 2nd 2019

Immuron delivers another year of strong sales growth

Australia’s top biotechs descend on Queenstown for the 2019 Bioshares Summit

July 25th 2019

Australia’s top biotechs descend on Queenstown for the 2019 Bioshares Summit

Trial success may open up options for BPH

July 3rd 2019

Trial success may open up options for BPH

Immuron’s shares rise on the back of  Travelan® results

June 12th 2019

Immuron’s shares rise on the back of Travelan® results

< prev Page 2 of 3 next >

Connect with us

EXPLORE

  • Finfeed Portfolio
  • Latest Articles
  • How It Works
  • Archived Articles
  • About StocksDigital
  • News
  • PORTFOLIOS

  • Next Investors
  • Catalyst Hunter
  • Wise-Owl
  • STOCKS

    FOLLOW OUR INVESTMENT COMMENTARY & ANALYSIS
      CUSTOMER NOTICE | PRIVACY POLICY | FINANCIAL SERVICES GUIDE | DISCLOSURE POLICY  
    The information in this website is general information only. Any advice is general advice only. Your personal objectives, financial situation or needs have not been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice. S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877).
    © 2021   |   AFSL (CAR No.433913)